Angle Health Raises $200M Series C at $2.7B — Plus a $400M Tender

Angle Health announced a $600 million equity package on September 18, 2026: $200 million Series C plus a $400 million tender, at a $2.7 billion valuation. Vitruvian Partners led. Town Hall Ventures joined; Blumberg Capital, Portage Ventures, PruVen Capital, and Y Combinator returned. Closing is expected later this month.

this is not another agent-only Series C. Angle discloses profitability, ~$1 billion annualized premium-equivalents, and 5,000+ employers — then uses two-thirds of the package for liquidity, not growth equity.

Not Angle Protocol.

Key facts

Who uses the product — and for what job

Users: U.S. small and midsize employers (as few as two employees in some states), brokers quoting groups, and employees navigating care.

Job: buy level-funded plans — predictable premiums with stop-loss, surplus sharing when claims stay low — without choosing pure fully insured (expensive, predictable) or pure self-funded (volatile). Angle’s Benefit Builder turns a census into underwritten quotes in minutes and layers AI navigation onto care pathways (meds, infusions, outpatient surgery, radiology partners named in the release).

That is an insurance + admin job, closer to a carrier/TPA replacement than to ICHRA budget tooling like Thatch.

Why now

• Employers face the largest health-cost jump in two decades (WSJ cite in Angle’s release) while SMB employment keeps growing.
• Portage’s prior $134M (Dec 2025, per TNW/WSJ) left a mark that this round more than doubles — growth capital arrives with a liquidity event for a 2019-founded company that claims GAAP profitability.
• Vitruvian’s Jeremy Gelber quote frames “industry-leading growth and retention” plus “financial stability” — the Series C sells durable P&L, not a research demo.

Why Vitruvian — portfolio fit

Vitruvian is a London-rooted global growth firm (\$23B+ active funds in its About copy) with healthcare and asset-light tech scale-ups on its list. Angle asked for healthcare × technology × financial-services expertise — the Strategic rationale in the release is explicit.

Y Combinator returning keeps batch signal on a W20 alum now at growth scale. Town Hall adds U.S. health-policy credibility. Portage returning from Series B continuity. **

Strategic rationale: take a growth lead that can follow for years, open a large tender so early holders and employees do not force a sale, and keep YC for talent without needing a U.S. mega-fund to own the round.

Competitive map

• ICHRA platforms (e.g. Thatch) — different product; individual budgets vs level-funded group plans.
• Incumbent carriers / TPAs — Angle’s stated foil on opacity and renewal spikes.
• Broker tools without risk — Angle carries insurance economics; diligence must include loss ratios, not only software margins.

What remains undisclosed

• Exact primary vs secondary ownership after close.
• Whether $2.7B is pre- or post-money wording beyond “valuation.”
• Audited financials behind the GAAP profitability claim.
• Net dollar retention and broker concentration.

Implication

If the profitability and renewal claims hold, Angle is a bet that SMB health admin can look like growth software with an insurance float — and that European growth capital will pay up for U.S. benefits platforms that print cash, not just agent demos. The open question is whether the $400M tender at a lower secondary mark becomes the template for late-stage healthtech liquidity without an IPO.

Sources

1. Angle Health announcement (Sep 18, 2026): https://www.anglehealth.com/post/angle-health-secures-series-c-financing
2. TechCrunch: https://techcrunch.com/2026/09/18/y-combinator-insurance-tech-alum-angle-health-hits-2-7b-valuation/
3. The Next Web (WSJ secondary mark): https://thenextweb.com/news/angle-health-600m-vitruvian-partners-2-7bn-valuation